Brind.

FDA adverse event reports led to a stock drop for Agios Pharmaceuticals, which was reported by investing.com.

1 report, 1 independent Updated Aug 4

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA Agios Pharmaceuticals

Keep exploring

The entities involved

FDA
- Indian products were subject to an FDA recall.10:25
- FDA and HHS jointly presented food safety reforms, reviewing ultraprocessed food definitions and calling for congressional action on the GRAS program.06:54
Agios Pharmaceuticals
a public American pharmaceutical company

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 4Investing.comAgios shares drop after report notes deaths of Pyrukynd patients Investing.com -- Agios Pharmaceuticals stock is falling 15% in premarket trading Monday after the FDA’s Adverse Events Reporting Syste